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Background and purpose — To further improve the success of 
joint replacement surgery, attention needs to be paid to variations 
associated with improved or worsened outcomes. We investigated 
the association between the type of bone cement used and the risk 
of revision surgery after primary total hip replacement.
Methods — We conducted a prospective study of data from the 
National Joint Registry for England and Wales between April 1, 
2003 and December 31, 2013. 199,205 primary total hip replace-
ments performed for osteoarthritis where bone cement was used 
were included. A multilevel over-dispersed piecewise Poisson 
model was used to estimate differences in the rate of revision by 
bone cement type adjusted for implant type, head size, age, sex, 
ASA grade, and surgical approach. 
Results — The rate of revision was higher in DePuy CMW3 
medium viscosity with gentamicin (IRR 2.0, 95% CI 1.5–2.7) and 
DePuy SmartSet high viscosity plain (IRR 2.7, 95% CI 1.1–5.5), 
and lower in DePuy CMW1 high viscosity plain (IRR 0.44, 95% 
CI 0.19–0.89) bone cements compared with Heraeus Palacos high 
viscosity with gentamicin. Revision rates were similar between 
plain and antibiotic-loaded bone cement.
Interpretation — The majority of bone cements performed sim-
ilarly well, excluding DePuy SmartSet high viscosity and CMW3 
high viscosity with gentamicin, which both had higher revision 
rates. We found no clear differences by viscosity or antibiotic con-
tent. 
■
Cemented fi xation of total hip replacements (THR) is asso-
ciated with low rates of revision surgery in registry studies 
(Makela et al. 2014, NJR Steering Committee 2015b) in com-
parison with uncemented. There have been a limited number 
of observational reports describing the effi cacy of different 
bone cements (BC) but it is unclear whether different BCs 
lead to different revision rates. For example, DePuy CMW3 
(Havelin et al. 1995, 2000, Espehaug et al. 2002), DePuy 
CMW1 (Espehaug et al. 2002) and Sulfi x (Herberts and Mal-
chau 2000) BCs have previously been noted to be associated 
with higher failure rates. 
Crudely, BCs can be categorized by their viscosity and 
antibiotic content. The choice of viscosity is primarily 
determined by the type of operation and surgeon prefer-
ence. There have been previous reports of increased failure 
rates with low-viscosity BCs (Herberts and Malchau 2000); 
however, conversely high-viscosity BCs have also been 
implicated (Espehaug et al. 2002). Antibiotic-loaded bone 
cements (ABC) are used in over 90% of all cemented fi xa-
tions in countries in which cemented fi xation is commonly 
used (Blom et al. 2003, Lindgren et al. 2014). The prophy-
lactic routine use of ABC appears sensible; however, the evi-
dence to support its use is heterogeneous. An observational 
study using data from the Norwegian Arthroplasty Register 
showed lower rates of revision for primary THR using ABC 
with systemic antibiotics in comparison with plain BC with 
systemic antibiotics (Engesaeter et al. 2003). There are only a 
small number of randomized trials that have investigated the 
effi cacy of ABC in humans (Pfarr and Burri 1979, Wannske 
and Tscherne 1979, Josefsson et al. 1981, McQueen et al. 
1987, 1990, Chiu et al. 2002, Hinarejos et al. 2013). A recent 
systematic review concluded that antibiotic loading is justi-
fi ed in reducing PJI (Wang et al. 2013). However, the authors 
failed to include 1 eligible study in their meta-analysis (Pfarr 
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and Burri 1979), and opted to use the short-term follow-up 
results from a trial as opposed to the long-term results (10 
years), which were also available (Josefsson and Kolmert 
1993). A sensitivity analysis (see Supplementary data) illus-
trates no effect of ABC (Table 1, see Supplementary data), 
and regression to the null over time (Figure 1, see Supple-
mentary data). 
We investigated the association between the type of BC used 
and the subsequent risk of revision in individuals undergoing 
primary THR, and whether any differences in revision rates 
could be explained by antibiotic content.
Methods
Using data from the National Joint Registry (NJR) for Eng-
land, Wales and Northern Ireland, we investigated the asso-
ciation between BC brand, viscosity, antibiotic loading, and 
revision surgical procedure in patients undergoing THR. 
Reporting follows recommendations of the STROBE initia-
tive (Strengthening the Reporting of Observational Studies in 
Epidemiology) (von Elm et al. 2007). 
Data source
The initial NJR dataset included 710,177 primary THR pro-
cedures performed in England and Wales between April 1, 
2003 and December 31, 2013. Compliance, a measure of 
completeness comparing the number of procedures recorded 
in the NJR with implant sales, was low initially at 43% in 
2003/04, but above 80% since 2005/06 and above 90% since 
2007/08 (NJR Steering Committee 2015c). An audit of hip 
procedures for the fi nancial year 2014/15 comparing hospital 
patient administration systems data with the NJR found that 
4.3% of primary hip procedures and 8.1% of hip revisions 
were missing from the NJR (NJR Steering Committee 2016). 
Patient details for individuals with a traceable National Health 
Service (NHS) number (unique patient identifi er) were passed 
to the NHS Personal Demographics Service, which provided 
date of death from the Offi ce for National Statistics (ONS). 
Primary procedures were then linked to revisions in the NJR 
with available patient identifi ers (anonymized NHS number 
and side of procedure). 
Inclusion/exclusion criteria
All cemented (cup and stem cemented), hybrid (uncemented 
cup and cemented stem), and reverse hybrid (cemented cup 
and uncemented stem) THRs, where the only recorded indica-
tion for surgery was osteoarthritis, were included in this study. 
Procedures where more than 1 type of BC was used, consent 
was withdrawn, the patient was untraceable, or with missing 
or inconsistent information on any of the study variables were 
excluded (Figure 2). The analysis was restricted to procedures 
with implant combinations that were used in at least 500 pro-
cedures. This included the 62 most commonly used combina-
tions (out of 2,023) and accounted for 80% of all recorded 
procedures (Figure 3, see Supplementary data). BCs that had 
less than 100 implantations were excluded. 
Primary outcome
The primary outcome in this study was the fi rst surgical revi-
sion of a primary THR. First surgical revision is determined 
using the mandatory registration of arthroplasty procedures in 
England and Wales. Loss to follow-up occurs with migration 
outside of England and Wales and when procedures are not 
entered onto the register. Linkability is estimated to be greater 
than 96% since 2008 (NJR Steering Committee 2015b). Left 
and right THRs in the same patient were considered to be 
independent and were counted as 2 observations, as the choice 
of prostheses and BCs between sides was not constrained to 
be the same. 
The follow-up time from the date of the primary procedure 
to either the fi rst revision or censoring (death or end of follow-
up) was calculated using linked data from the ONS. The maxi-
mum possible follow-up time was 11 years.
Exposure
The primary exposure in this study was the use of polymethyl-
methacrylate BC to achieve fi xation of at least 1 implant in the 
Figure 2. Patient inclusion in/exclusion from the study.
a 44,179 individuals from England and Wales were not traceable. 
Northern Ireland joined the NJR on February 1, 2013; however, there 
was no tracing service available for patients in Northern Ireland, and 
609 procedures were therefore excluded from the analysis.
Excluded (n = 460,649):
– withdrew consent, 41,413
– not traceable a, 44,788
– missing date information, 3
– > 1 operation recorded as primary, 6,620
– recorded date of death prior to operation, 37
– reason for surgery not only osteoarthritis, 63,885
– aged under 40 or missing/inconsistent age, 4,773
– duplicate, missing or inconsistent implant 
   information, 18,969
– uncemented implants, 205,934
– resurfacings, 29,864
– no bone cement, 11,809
– > 1 type of bone cement used, 32,484
– unknown gender, 7
– ASA grade 5, 63
Excluded (n = 50,323):
– implant type used in < 500 operations, 49,824
– cement type used in < 100 operations, 499
Primary hip operations
n = 710,177
Primary hip operations
n = 249,528
Primary hip operations
n = 199,205
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total hip replacement. The BCs (regardless of volume, mixing 
system, or delivery mechanism) were grouped into 9 brands 
(Table 3). Cement type was further sub-classifi ed based on the 
manufacturer-reported viscosity (high (HV), medium (MV) or 
low (LV)), and antibiotic content.
Confounders
The primary confounding factor was implant type, defi ned 
using: stem, head, and cup combinations. Other confounding 
factors also included in the analysis were age (40–54, 55–64, 
65–74, 75–85, and > 85 years), sex, ASA grade (graded 1–4), 
implant head size (22.25 mm, 26 mm, 28 mm, 30–32 mm, and 
> 36 mm), and surgical approach (“posterior” or “other”).
Statistics
The crude revision rate and prosthesis time incidence rate 
(PTIR; rate per 1,000 prosthesis-years of follow-up) of revi-
sion by BC type are reported. A multilevel over-dispersed 
piecewise Poisson model was used to estimate differences 
in the rate of revision by BC type. Multilevel modelling was 
used as it provides an effi cient and transparent method of 
controlling for confounding factors either in the random or 
fi xed-effects structure, whilst allowing for violations to key 
modelling assumptions, i.e. over-dispersion. Over-dispersion 
was controlled by the inclusion of a hyper-variance param-
eter within the random effects. Control for the primary con-
founding factor was achieved by matching procedures using 
the same implant combinations together and then investigat-
ing the difference in BC types. The length of prosthesis fol-
low-up was included in the model via an offset parameter. A 
piecewise approach was adopted to allow for the time varying 
risk of revision; < 6 months, 6 months to 1 year, 1 year to 5 
years, and > 5 years. Missing data are assumed to be missing 
at random, and therefore complete case analysis is assumed to 
be unbiased given the large sample size.
We adopted a progressive confounding adjustment strat-
egy. The fi rst model was minimally adjusted for implant type 
by the use of a grouping indicator in the random effects to 
preserve matching. We then compared this with models that 
were more fully adjusted for age, sex, ASA grade, surgical 
approach, and implant head size. These additional confound-
ing factors were included as fi xed effects. Results are reported 
with reference to Heraeus Medical Palacos HV BC with gen-
tamicin (the most commonly used cement).
The analysis was performed using MLwiN 2.35 (Browne 
2009, Rasbash et al. 2009) with the runmlwin command 
(Leckie and Charlton 2013) in Stata 13 (StataCorp LP, Col-
lege Station, TX, USA). Models were estimated using Markov 
Chain Monte Carlo methods (Browne and Draper 2006). 
Results are reported as incidence rate ratios (IRR) with 95% 
credible intervals (CI) and directional posterior probabilities 
(p). Directional posterior probabilities are reported as opposed 
to p-values to avoid the commonly misheld interpretation of 
a p-value that it provides evidence that the parameter is the 
wrong side of the null hypothesis of no effect (Greenland and 
Poole 2013). Effective sample size (ESS) is also reported to 
indicate the amount of chain mixing. 
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Availability of data and material
The data that support the fi ndings of this study are available 
from the National Joint Registry for England, Wales, North-
ern Ireland and the Isle of Man but restrictions apply to the 
availability of these data, which were used under license 
for the current study, and so are not publicly available. Data 
access applications can be made to the National Joint Registry 
Research Committee.
Results
The initial NJR dataset included 710,177 primary THR pro-
cedures. Following application of the inclusion/exclusion cri-
teria listed previously (Figure 2) there were 199,205 primary 
THR procedures remaining.
Descriptive results
The majority of procedures were carried out on women (65%); 
however, the distribution of age, ASA physical status, surgical 
approach, fi xation, bearing surface, and head size were very 
similar between men and women (Table 2).
Of the 199,205 included primary THRs, 2,494 (1.25%) had 
a linked revision (Table 3). The total follow-up time for all 
procedures was 813,034 prosthesis years. The overall PTIR of 
revision was 3.07/1,000 prosthesis-years. The average follow-
up time for a procedure was 4.08 years (Table 4, see Supple-
mentary data). 
Heraeus Medical Palacos HV BC with gentamicin was 
used in 49% of all procedures and had a PTIR of 3.29/1,000 
prosthesis-years. DePuy SmartSet HV plain BC had the high-
est PTIR at 7.36/1,000 prosthesis-years, followed by DePuy 
CMW3 MV BC with gentamicin at 6.21/1,000 prosthesis-
years. 
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Multilevel over-dispersed piecewise Poisson regres-
sion model
Similar results were seen in the minimally and fully adjusted 
models (Table 5, see Supplementary data). For the majority of 
cements, in the fully adjusted model, there was no evidence 
of a difference in revision rate when compared with Heraeus 
Palacos HV with gentamicin, i.e. the CI includes the null. 
However, the rate of revision appears to be 103% higher in 
DePuy CMW3 MV with gentamicin (IRR 2.0, CI 1.5–2.7) and 
165% higher in DePuy SmartSet HV plain (IRR 2.7, CI 1.1–
5.5) BCs respectively. However, the revision rate using DePuy 
CMW1 HV plain BC is 56% lower (IRR 0.44, CI 0.19–0.89) 
compared with the referent. The IRR (with CI), in the fully 
adjusted model, for all cement types, are presented using a 
forest plot in Figure 4. When each ABC was compared with 
its plain BC variant (Figure 5) there was no evidence of an 
increased risk of revision with the use of plain BC. In addition, 
there were no clear differences in the reason for revision com-
paring ABC and plain BC (Table 6, see Supplementary data). 
Similarly, the evidence of an effect of HV vs. MV and LV is 
minimal, with no clear association within or between brands.
Discussion
This study has demonstrated in 199,205 primary hip replace-
ment procedures that a small number of BCs are associated 
with an increased risk of revision surgery. Using the most 
commonly used BC as our reference (Heraeus-Medical Pala-
cos HV with gentamicin) and adjusting for confounding fac-
tors (age, sex, ASA grade, surgical approach, and implant 
head size), we have demonstrated there is an increased risk 
of revision surgery with DePuy CMW3 MV with gentamicin 
and DePuy SmartSet HV plain BCs. DePuy CMW1 HV plain 
BC demonstrated a reduced risk of revision. There are no clear 
patterns of failure associated with BC viscosity. Most nota-
bly the Stryker Simplex MV family of cements perform very 
similarly in comparison with the 3 most commonly used HV 
cements (Heraeus Palacos HV, Schering-Plough Palacos HV, 
and Biomet HV). Similarly, there is a surprising lack of dif-
ference between ABCs and plain BCs. This consistency is evi-
dent across all 4 manufacturers, with the exception of DePuy 
CMW1 HV plain, which outperforms the antibiotic-loaded 
variant, and DePuy SmartSet HV with gentamicin, which out-
performs the plain variant. 
Table 2. Demographic and surgical characteristics at the 
time of the primary procedure
 Women Men
Variable n   (%) n   (%)
Age (years) 
 40–54 3,943 (3) 2,633 (4)
  55–64 18,346 (14) 11,489 (16)
  65–74 49,140 (38) 29,249 (41)
  75–84 47,546 (37) 23,550 (33)
   85 9,745 (8) 3,564 (5)
ASA physical status 
 1 16,430 (13) 10,111 (14)
  2 91,922 (71) 47,623 (68)
  3 19,774 (15) 12,295 (17)
  4 594 (0) 456 (1)
Surgical approach
 Posterior 65,274 (51) 36,196 (51)
  Other 63,446 (49) 34,289 (49)
Fixation 
 Cemented 87,928 (68) 45,899 (65)
  Hybrid 35,537 (28) 21,643 (31)
  Reverse hybrid 5,255 (4) 2,943 (4)
Bearing surface 
 MoP 112,999 (88) 59,696 (85)
  CoP 9,633 (7) 6,528 (9)
  CoC 6,088 (5) 4,261 (6)
Head size (mm) 
 22.25 12,374 (10) 6,170 (9)
  26 8,210 (6) 3,931 (6)
  28 78,479 (61) 38,334 (54)
  30–32 20,959 (16) 14,336 (20)
  36 8,698 (7) 7,714 (11)
Table 3. Number of primary procedures, revisions, crude revision rate, and 
PTIR by cement type
    Crude 
  Primary  revision 
Manufacturer procedures Revised rate 
 Brand Viscosity Antibiotic   n   (%) n (%) PYAR PTIR
All   199,205 (100) 2,494 1.25 813,034 3.07
Heraeus Medical
 Palacos HV G 97,956 (49.2) 988 1.01 299,985 3.29
 Palacos HV – 499 (0.3) 4 0.80 1,531 2.61
 Palacos MV G 379 (0.2) 2 0.53 1,374 1.46
 Palacos LV G 1,069 (0.5) 16 1.50 4,438 3.61
Stryker
  Simplex MV T 14,982 (7.5) 176 1.17 59,474 2.96
 Simplex MV E/C 13,913 (7.0) 170 1.22 63,516 2.68
 Simplex MV – 4,733 (2.4) 78 1.65 25,852 3.02
Schering-Plough
  Palacos HV G 26,270 (13.2) 499 1.90 178,318 2.80
 Palacos HV  – 1,620 (0.8) 23 1.42 10,447 2.20
 Palacos LV G 1,156 (0.6) 34 2.94 8,463 4.02
Biomet
 Palacos HV G 235 (0.1) 3 1.28 1,492 2.01
 Palacos HV  – 1,143 (0.6) 18 1.57 5,556 3.24
 Biomet HV G 18,495 (9.3) 229 1.24 77,584 2.95
DePuy
 CMW 1 HV G 6,841 (3.4) 99 1.45 33,854 2.92
 CMW 1 HV  – 800 (0.4) 7 0.88 4,583 1.53
 CMW 2 HV G 3,418 (1.7) 34 0.99 10,158 3.35
 CMW 2 HV – 506 (0.3) 9 1.78 2,306 3.90
 CMW 3 MV G 1,887 (0.9) 53 2.81 8,532 6.21
 SmartSet HV G 3,096 (1.6) 45 1.45 14,620 3.08
 SmartSet HV  – 207 (0.1) 7 3.38 950 7.36
Viscosity: HV = high, MV = medium, LV = low. 
Antibiotics: G = gentamicin, T = tobramycin, E/C = erythromycin/colistin. 
PYAR = prosthesis years at risk. 
PTIR = prosthesis time incidence rate, per 1,000 prosthesis-years. 
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Whilst this study is signifi cantly larger than many of the pre-
vious studies investigating BCs, it confi rms the previous fi nd-
ings of the Nordic registries, which suggest DePuy CMW3 
has a higher revision rate than the reference BC (Havelin et 
al. 1995, 2000, Espehaug et al. 2002). In the Nordic registries 
DePuy CMW3 was previously described as LV (Herberts and 
Malchau 2000), but in the data supplied to NJR it is described 
by the manufacturer as MV. Conversely we have found the 
DePuy CMW1 HV plain BC signifi cantly outperforms the 
most frequently used BC, which is contradictory to previous 
reports (Espehaug et al. 2002). This discrepancy may be due 
the restriction of the previous analysis to Charnley THRs, 
which make up a small proportion of the constructs included 
in this analysis and use a different fi xation strategy for the 
stem (Learmonth 2006) than the majority of the cemented 
constructs included here (NJR Steering Committee 2015b). 
Figure 4. Incident rate ratio (95% CI) of revision surgery comparing different bone cements with Heraeus Palacos HV+gentamicin. 
Abbreviations are G = gentamicin, T = tobramycin, E/C = erythromycin/colistin, HV = high, MV = medium, LV = low viscosity. Point 
estimates are weighted by sample size to illustrate the number of procedures to estimate the cement type IRR.
Figure 5. Incident rate ratio (95% CI) of revision surgery comparing antibiotic-loaded cement with its plain variant. For 
abbreviations, see Figure 4.
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However, it is probably prudent to interpret the evidence of 
superiority for this BC cautiously given the relatively small 
number of procedures in which it is used.
The level of homogeneity in revision rates associated with 
different BCs is surprising, specifi cally with respect to the 
performance of ABC when compared with plain BC. We 
would expect the use of plain BC to lead to an excess of revi-
sion due to PJI. Given that this does not seem to be the case, 
it calls into question the prudence of such widespread use of 
ABC. The use of ABC in the UK is highly prevalent, with 
over 95% (90% in the NJR overall (NJR Steering Commit-
tee 2015a)) of prostheses in this sample using ABC, strongly 
suggesting that it is not being used in a selective way by sur-
geons depending on any risk assessment of PJI. However, the 
use of ABC has potential consequences including antibiotic 
resistance and excess treatment costs. Whilst the current rate 
of antibiotic-resistant bacterial infections in this cohort is 
relatively low (Hickson et al. 2015), we do not know if this 
will persist. 
Including antibiotics within BC is supposed to reduce the 
risk of PJI and therefore revision surgery. However, it is not 
clear whether ABC—with or without the concomitant use of 
systemic antibiotics—reduce the risk of infection after total 
joint replacement (see Supplementary data). Lack of contem-
porary evidence in favor of the use of ABC could be explained 
by other perioperative effects that infl uence the risk of PJI, 
such as reduced operating time and increased use of laminar 
fl ow theatres over the period of interest. Given the similar 
number of revisions due to PJI in ABC compared with plain 
BC in this sample, it seems to suggest that contemporary 
evidence of effi cacy is lacking. Registry data tend to under-
estimate the number of revisions due to infection (Gundtoft 
et al. 2016), although as we have used all-cause revision as 
our endpoint this should not affect our main results. Given 
the potential to induce antibiotic-resistant infections (Hope 
et al. 1989) and increased costs, the widespread use of ABC 
must be evidence based (WHO 2001, Larson 2007). The list 
price cost differential (excluding sales tax) between ABC 
and the plain BC variant for the reference group in this study 
(Heraeus Palacos HV BC) is £58 (USD 79) for patients 
undergoing cemented THR, and £39 (USD 53) in patients 
undergoing hybrid THR (assuming 2 x 40g BC packets for 
stem fi xation and 1 x 40g BC packet for cup fi xation; https://
my.supplychain.nhs.uk/Catalogue/browse/65/bone-cement-
and-mixing-devices). As approximately 50% of all THRs (n 
= 80,000) in England, Wales, and Northern Ireland in 2014 
used BC the potential annual savings are substantial (NJR 
Steering Committee 2015b). Furthermore, if the prolifi c use 
of ABC may lead to an increase in the number of antibiotic-
resistant infections the cost of treating these infections must 
also be considered. Parvizi et al. (2010) reported that mean 
excess cost of treating infection caused by methicillin-resis-
tant organisms was USD 32,181 in 2010.
Strengths 
This study is the largest in vivo systematic investigation of 
the association between BC and revision surgery following 
primary THR. The unique design of the study, i.e. matched 
cohort study, allowed us to effectively control for the associa-
tion between the prosthetic implant and risk of revision. By 
explicitly comparing revision rates within the same implant 
combinations we have removed the largest source of con-
founding. Furthermore, the NJR is one of the largest registers 
of arthroplasty in the world and the heterogeneous use of BC 
and prosthetic implants in England and Wales has allowed us 
to explore the effi cacy of BC in a wide variety of contexts. 
Similarly the contemporary basis of the data strengthens the 
face validity, with operating practices being more consistent 
in the last 10 years.
Limitations 
Despite the large size of the database, half of cases in which 
BC was used were Heraeus Medical Palacos HV with genta-
micin. Therefore, the power to detect any differences in some 
of the less popular BCs is smaller. Given the magnitude of the 
effects reported and the length of the 95% credible intervals, 
we believe this is a fair representation of the performance of 
different BC currently used. The overall revision rate in our 
data is lower than the revision rate for cemented implants 
within the Nordic registries and the NJR. The NJR also has 
a lower revision rate for cemented procedures at 5 years than 
the Nordic registries. We have excluded from our analyses 
metal-on-metal procedures, which are known to have a higher 
revision rate. We also restricted our analyses to the most 
used implant combinations, which we would hope would be 
implant types with lower revision rates. Despite the NJR being 
one of the largest registries in the world, with very good com-
pliance and data completion rates (NJR Steering Committee 
2015b), as with all studies the potential for revision surgeries 
to be missing not at random has the potential to bias results. 
Similarly, residual confounding is still possible despite the 
rigorous methods adopted. 
The outcome for this study was all-cause revision. It would 
also be interesting to conduct analyses on cause-specifi c revi-
sion, particularly when investigating the effect of adding anti-
biotic to bone cement where the main difference would be 
expected to be for infections. However, as the revision rate is 
low we feel that such an analysis would likely be underpow-
ered and therefore not provide meaningful results. Lastly we 
cannot exclude the possibility that surgeons added antibiotics 
to plain BC products in theatre, which is not documented in 
the NJR.
In summary, the majority of BCs performed similarly well, 
excluding DePuy SmartSet HV and CMW3 HV with gentami-
cin, which both had higher revision rates. We found no clear 
differences by viscosity or by antibiotic content. 
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